InVivo Therapeutics Holdings Corp. (NVIV): Price and Financial Metrics


InVivo Therapeutics Holdings Corp. (NVIV): $7.98

3.62 (+83.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NVIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NVIV Stock Price Chart Interactive Chart >

Price chart for NVIV

NVIV Price/Volume Stats

Current price $7.98 52-week high $16.50
Prev. close $4.36 52-week low $3.50
Day low $4.25 Volume 1,544,683
Day high $7.98 Avg. volume 253,359
50-day MA $6.01 Dividend yield N/A
200-day MA $6.94 Market Cap 11.10M

InVivo Therapeutics Holdings Corp. (NVIV) Company Bio


InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 and is based in Cambridge, Massachusetts.


NVIV Latest News Stream


Event/Time News Detail
Loading, please wait...

NVIV Latest Social Stream


Loading social stream, please wait...

View Full NVIV Social Stream

Latest NVIV News From Around the Web

Below are the latest news stories about INVIVO THERAPEUTICS HOLDINGS CORP that investors may wish to consider to help them evaluate NVIV as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are the hot topic this morning as we cover all the latest news sending shares higher and lower on Monday!

William White on InvestorPlace | August 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning!

William White on InvestorPlace | August 5, 2022

What Is Going on With InVivo Therapeutics (NVIV) Stock Today?

InVivo Therapeutics (NVIV) stock is rocketing higher on Thursday despite a lack of news concerning the biotechnology company.

William White on InvestorPlace | August 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | August 4, 2022

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

CAMBRIDGE, Mass., July 13, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company’s legal and intellectual property functions, and provide strategic guidance to the company’s Board of Directors and executive management team

Yahoo | July 13, 2022

Read More 'NVIV' Stories Here

NVIV Price Returns

1-mo 50.28%
3-mo 102.03%
6-mo 6.40%
1-year -50.22%
3-year -97.86%
5-year -99.97%
YTD -30.02%
2021 -43.69%
2020 -87.99%
2019 -85.11%
2018 -92.16%
2017 -81.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5485 seconds.